MedPath

Investigation of inhaled Salmeterol/ Fluticasone propionate (SFC) in patient with COPD.

Phase 4
Conditions
Chronic obstructive pulmonary disease
Registration Number
JPRN-UMIN000006589
Lead Sponsor
Hamamatsu University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
342
Inclusion Criteria

Not provided

Exclusion Criteria

History of hyper- sensitivity to Salmeterol/ Fluticasone propionate Patients with bronchial asthma Patients during acute exacerbation Presence of infectious disease, pneumothorax, and severe heart failure

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes of FEV1
Secondary Outcome Measures
NameTimeMethod
QOL, Safety
© Copyright 2025. All Rights Reserved by MedPath